Chief Scientific Officer of $CARM sells 200,000 shares in insider sale

Chief Scientific Officer of $CARM, Michael Klichinsky, recently sold 200,000 shares of the company, amounting to approximately $50,860. This transaction represents about 62.6% of the total shares he held in this stock class and leaves him with 119,347 shares in this category of $CARM stock.

Over the past 6 months, $CARM insiders have engaged in trading this stock three times, with all three instances involving sales and no purchases. Michael Klichinsky, in particular, has made three sales, disposing of a total of 484,347 shares and receiving an estimated $124,342.

In terms of institutional activity related to $CARM, there have been notable moves by hedge funds. Vanguard Group Inc. removed a significant number of shares, totaling 1,045,284 shares or 74.9% of their holdings in Q2 2025, corresponding to approximately $409,333. Conversely, Jane Street Group, LLC added 150,810 shares to their portfolio during this period.

Moreover, there have been analyst ratings issued regarding $CARM in recent months. One firm provided a “Buy” rating on 08/08/2025, indicating a positive outlook for the stock. This information could be valuable for investors looking to make informed decisions regarding their investment strategies.

It is essential to note that the information presented in this article is not financial advice but rather data on recent insider trading, hedge fund activity, and analyst ratings related to $CARM. For a more comprehensive understanding of these elements, interested parties can explore Quiver Quantitative’s tools and resources to track insider transactions, hedge fund stock portfolios, and analyst forecasts.

In conclusion, the sale of $CARM shares by the Chief Scientific Officer, Michael Klichinsky, sheds light on recent trading activities within the company. Understanding insider transactions, hedge fund movements, and analyst recommendations can provide valuable insights for individuals interested in the financial performance of $CARM and its investment potential.